News
SAN FRANCISCO -- Crinecerfont (Crenessity) may help improve metabolic profiles of adults and children with classic congenital ...
The Co-STAR trial tested the performance of colchicine in preventing new-onset arrhythmias and subclinical leaflet thrombosis ...
The incidence of recurrent Clostridioides difficile infection was lower among at-risk patients on antibiotics for other ...
The American Academy of Dermatology has updated its guidelines for treating and managing atopic dermatitis with topical and ...
Rimegepant 75 mg for 52 weeks is well tolerated, with no liver safety signals and a sustained reduction in monthly migraine days, a new extension study shows.
In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...
1h
Verywell Health on MSN13 Anti-Aging Fruits to Add to Your DietEating vitamin C-rich fruits like raspberries can help slow skin aging. The vitamin supports collagen production, keeping skin firm, smooth, and youthful. Additional antioxidants in raspberries may ...
Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor the care providers, investigators, or outcome ...
Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...
2d
Vietnam Investment Review on MSNAscletis Completes Dosing in US Obesity Drug Combo TrialAscletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) ...
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results